| Christine Christophersen, APRN | |
|
25 Leavey Dr, Bedford, NH 03110 | |
| (603) 663-3740 | |
| Not Available |
| Full Name | Christine Christophersen |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 25 Leavey Dr, Bedford, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326592890 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elliot Professional Services | 6103727920 | 304 |
News Archive
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials. Ondansetron Injection USP, 2 mg/mL is the generic equivalent of GlaxoSmithKline's Zofran® Injection, 2 mg/mL. For the 12 months ending December 2009 U.S. sales of Ondansetron Injection USP, 2 mg/mL were approximately $58 million at Average Wholesale Price (AWP). A launch date for the product has not yet been set.
Omega-3, the fatty acid found in oily fish, could be combined with a commonly used anesthetic to develop drugs to treat breast cancer, according to research published in the journal Breast Cancer Research.
"AIDS activists gathering in Washington, D.C., and Kolkata, India, this week have denounced conditions attached to U.S. global AIDS funding, which they say have damaged the response to the epidemic by further marginalizing sex workers - among those hardest hit" by the epidemic, the Guardian reports.
Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015. Identifying those men who have a higher risk of developing prostate cancer may reduce mortality.
A new study in the journal Respirology reveals that patients with diabetes who are hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) experience longer time in the hospital and are also at an increased risk of death, compared to those without diabetes.
› Verified 8 days ago
| Entity Name | Elliot Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285627935 PECOS PAC ID: 6103727920 Enrollment ID: O20040115000634 |
News Archive
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials. Ondansetron Injection USP, 2 mg/mL is the generic equivalent of GlaxoSmithKline's Zofran® Injection, 2 mg/mL. For the 12 months ending December 2009 U.S. sales of Ondansetron Injection USP, 2 mg/mL were approximately $58 million at Average Wholesale Price (AWP). A launch date for the product has not yet been set.
Omega-3, the fatty acid found in oily fish, could be combined with a commonly used anesthetic to develop drugs to treat breast cancer, according to research published in the journal Breast Cancer Research.
"AIDS activists gathering in Washington, D.C., and Kolkata, India, this week have denounced conditions attached to U.S. global AIDS funding, which they say have damaged the response to the epidemic by further marginalizing sex workers - among those hardest hit" by the epidemic, the Guardian reports.
Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015. Identifying those men who have a higher risk of developing prostate cancer may reduce mortality.
A new study in the journal Respirology reveals that patients with diabetes who are hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) experience longer time in the hospital and are also at an increased risk of death, compared to those without diabetes.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christine Christophersen, APRN 462 Manchester Rd, Auburn, NH 03032-3114 Ph: () - | Christine Christophersen, APRN 25 Leavey Dr, Bedford, NH 03110 Ph: (603) 663-3740 |
News Archive
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials. Ondansetron Injection USP, 2 mg/mL is the generic equivalent of GlaxoSmithKline's Zofran® Injection, 2 mg/mL. For the 12 months ending December 2009 U.S. sales of Ondansetron Injection USP, 2 mg/mL were approximately $58 million at Average Wholesale Price (AWP). A launch date for the product has not yet been set.
Omega-3, the fatty acid found in oily fish, could be combined with a commonly used anesthetic to develop drugs to treat breast cancer, according to research published in the journal Breast Cancer Research.
"AIDS activists gathering in Washington, D.C., and Kolkata, India, this week have denounced conditions attached to U.S. global AIDS funding, which they say have damaged the response to the epidemic by further marginalizing sex workers - among those hardest hit" by the epidemic, the Guardian reports.
Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015. Identifying those men who have a higher risk of developing prostate cancer may reduce mortality.
A new study in the journal Respirology reveals that patients with diabetes who are hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) experience longer time in the hospital and are also at an increased risk of death, compared to those without diabetes.
› Verified 8 days ago
Ashley Danielle Blazon, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 160 S River Rd, Bedford, NH 03110 Phone: 603-537-1300 Fax: 603-310-0191 | |
Megan E Leonard, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 201 Riverway Pl, Bedford, NH 03110 Phone: 603-668-8400 | |
Mrs. Patricia A Pappal, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 360 Route 101, Unit 10, Bedford, NH 03110 Phone: 603-472-2846 | |
Ms. Amanda Sadat, MA Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 15 Constitution Dr, Suite 1a, Bedford, NH 03110 Phone: 603-310-5026 Fax: 603-218-6187 | |
Sarah Wheeler, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 160 S River Rd, Bedford, NH 03110 Phone: 603-537-1300 Fax: 603-310-0191 | |
Alex Mutuku, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 188 Nh 101, Bedford, NH 03110 Phone: 603-314-4700 | |
Ashley Marie Lougee, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 25 Leavey Dr, Bedford, NH 03110 Phone: 603-472-7233 |